Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569919 | 0.90 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2MEN1 | |
| SCHEMBL5566651 | 0.90 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2MEN1 | |
| SCHEMBL30837987 | 0.89 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2MEN1 | |
| SCHEMBL9886817 | 0.81 | MEN1 (0.47) | SMYD2CYP3A4HTTSMN1; SMN2MEN1 | |
| SCHEMBL20500291 | 0.81 | MEN1 (0.47) | SMYD2CYP3A4HTTSMN1; SMN2MEN1 | |
| SCHEMBL7203588 | 0.81 | MEN1 (0.47) | SMYD2CYP3A4HTTSMN1; SMN2MEN1 | |
| SCHEMBL18866542 | 0.80 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3702277 | 0.77 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL24312364 | 0.77 | SMN1; SMN2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5488886 | 0.77 | LTA4H (0.42) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |